ARRAY BIOPHARMA - Home
 
 
 
  Array BioPharma
3200 Walnut Street
Boulder, CO 80301

Phone: 303.381.6600

  
  Site Map | Privacy Policy | Legal
  Copyright © 2010 Array BioPharma
All Rights Reserved
 
Patents & Publications
Publications   |   Patents   |   Posters & Presentations

Keyword Search
 
Below are scientific posters that have been presented at scientific conferences and that relate to Array's proprietary research programs or research collaborations with other biotechnology or pharmaceutical companies.
13th World Congress on Pain
8/31/2010
ARRY-797, a Small Molecule p38α Inhibitor, Has a Good Safety Profile and Provides Pain Relief in Clinical Studies
J.D. Winkler, et al.
Open PDF File >>
13th World Congress on Pain
8/31/2010
Analgesic Effects of a Potent and Selective Kinase Inhibitor of Neurotrophin Receptors TrkA, TrkB and TrkC
Karyn S. Bouhana, et al.
Open PDF File >>
American Chemical Society 2010 National Meeting & Exposition
8/22/2010
Development of Potent and Selective MMP Inhibitors with a Triazole Zinc Binding Group
Julia Haas, et al.
Open PDF File >>
Annual European Congress of Rheumatology 2010
6/17/2010
Treatment of Rheumatoid Arthritis with a MEK Inhibitor: Results of a 12-Week, Randomized, Placebo-Controlled Phase 2 Study in Patients with Active Rheumatoid Arthritis on a Background of Methotrexate
J Kay, et al.
Open PDF File >>
American Society of Clinical Oncology 2010 Annual Meeting
6/7/2010
A Phase 1 Safety and Pharmacokinetic Study of ARRY-520 in Solid Tumors
P. Goncalves, et al.
Open PDF File >>
American Society of Clinical Oncology 2010 Annual Meeting
6/5/2010
Phase 1 Trial of ARRY-520 in Relapsed/Refractory Multiple Myeloma
J. Shal, et al.
Open PDF File >>
2010 Society for Investigative Dermatology Annual Meeting
5/5/2010
A Potent and Selective CRTh2 Antagonist is Efficacious in a Model of Atopic Dermatitis
Laurence E. Burgess, et al.
Open PDF File >>
AACR National Conference
4/20/2010
Investigation of the growth inhibitory activity of the MEK inhibitor ARRY-438162 in combination with everolimus in a variety of KRas and P13K pathway mutant cancers
Brian Tunquist, et. al.
Open PDF File >>
AACR National Conference
4/20/2010
Single-agent Chk1inhibition is anti-proliferative in leukemia cells in vitro and in vivo
Kurtis Davies, et. al.
Open PDF File >>
AACR National Conference
4/20/2010
AR-mTOR-26 - A potent, selective mTORC 1 / 2 kinase inhibitor for the treatment of malignancy
Stefan D. Gross, et. al.
Open PDF File >>
AACR National Conference
4/19/2010
ARRY-162, A Potent and Selective MEK 1 / 2 Inhibitor, Shows Enhanced Efficacy in Combination with Other Targeted Kinase Inhibitors and with Chemotherapy
Rich Woessner, et. al.
Open PDF File >>
AACR National Conference
4/19/2010
Preclinical Development of ARRY-162, A Potent and Selective MEK 1 / 2 Inhibitor
Patrice Lee, Ph.D., et. al.
Open PDF File >>
AACR 101st Annual Meeting 2010
4/17/2010
Inhibitors as activators The dual nature of RAF inhibitors
Georgia Hatzivassiliou, Ph.D.
Open PDF File >>
American Academy of Allergy, Asthma & Immunology: 2010 Annual Meeting
2/27/2010
Potent and Selective CRTh2 Antagonists are Efficacious in Models of Asthma, Allergic Rhinitis and Atopic Dermatitis
Laura L. Carter, et al.
Open PDF File >>

 
 
 
Email this page
Printer friendly version